( RICS:DPRM )

News from D-Pharm Ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 21, 2015, 09:44 ET D-Pharm Succeeds to Raise 12.8M NIS in Rights Offering

D-Pharm Ltd (TASE: DPRM) announced today 21st January, 2015, successful completion of fundraising via a public rights issue, of 12.8M NIS in...


Dec 18, 2014, 08:00 ET D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA

D-Pharm Ltd. (TASE: DPRM) reported today, December 18th, 2014, that its Phase 2 clinical study of THR-18 successfully achieved its primary...


Nov 04, 2014, 08:51 ET D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA

D-Pharm Ltd (TASE: DPRM) reported today, November 4th, 2014, top-line safety results following completion of its Phase 2 clinical study of THR-18...


Jun 02, 2014, 08:00 ET D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA

D-Pharm Ltd. (TASE: DPRM), Rehovot, Israel, reports today, June 2nd, 2014, the interim results for the second dose tier of stroke patients that...


Jan 21, 2014, 08:00 ET D-Pharm Completes Recruitment of Patients into the first Dosage Tier of its Phase 2 Study with THR-18 in Acute Stroke Patients Treated with tPA

D-Pharm Ltd (TASE: DPRM) announced today, January 21st, 2014, that enrolment of patients into the first tier of its Phase 2 clinical trial with...


Jan 14, 2014, 08:00 ET D-Pharm Announces Recruitment of the First Patient Into Its Phase 2 Clinical Trial With DP-b99 in Acute High-Risk Pancreatitis

D-Pharm Ltd (TASE: DPRM) announced today January 14th 2014, that the first patient has been recruited into its Phase 2 clinical trial of DP-b99 in...


Nov 21, 2013, 08:00 ET D-Pharm starts Phase 2 Clinical Study with DP-b99 in Acute High-Risk Pancreatitis Patients

D-Pharm Ltd (TASE:DPRM) announced today November 21st 2013, receipt of approval from the regulatory authorities in Slovakia to commence a Phase 2...


Oct 30, 2013, 09:01 ET D-Pharm Granted Patent in US and China for its Phase II Product THR-18

D-Pharm Ltd (TASE: DPRM) announced today, October 30 2013, that a new patent has been granted in the US and China related to composition and use...


Oct 30, 2013, 08:00 ET D-Pharm Granted Patent in US and China for its Phase II Product THR-18

D-Pharm Ltd (TASE: DPRM) announced today, October 30 2013, that a new patent has been granted in the US and China related to composition and use...


Oct 16, 2013, 08:00 ET D-Pharm Commences Phase 2 Study with THR-18 In Stroke Patients Treated with Tissue Plasminogen Activator (tPA)

D-Pharm Ltd (TASE: DPRM) announced today, October 16th 2013, receipt of approval from the regulatory authorities in the Ukraine to commence a...


Oct 14, 2013, 09:00 ET D-Pharm Schedules Investigators Meeting to Discuss Protocol of Phase 2 Clinical Study of DP-b99 for Acute High-Risk Pancreatitis

D-Pharm Ltd (TASE: DPRM) announced today October 14th 2013, that an Investigators Meeting has been scheduled later this month, in Prague, to...


Aug 19, 2013, 09:00 ET Positive Results for D-Pharm's Investigational Drugs in Models of Human African Trypanosomiasis and Malaria

D-Pharm Ltd., (TASE: DPRM) announced today on-line publication of promising results with its drug candidates, DP-460 and DP-b99, in models of...


Oct 31, 2011, 12:54 ET D-Pharm Announces Expected Date of Interim Report for the DP-b99 Acute Ischemic Stroke Study, MACSI

D-Pharm Ltd., (TASE: DPRM) announced today that the interim report for the DP-b99 MACSI study is expected in February, 2012. The report will be...


Aug 24, 2011, 08:00 ET KFDA Grants IND Approval for Phase III MACSI Study of DP-b99 in Korea

D-Pharm Ltd., (TASE: DPRM) announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug (IND)...


Jul 20, 2011, 10:03 ET D-Pharm Receives Nod From DSMB to Continue the DP-b99 MACSI Phase III Study in Stroke Patients

  D-Pharm Ltd., (TASE: DPRM) announced today that the Data and Safety Monitoring Board (DSMB) for the Membrane Activated Chelator Stroke...


May 31, 2011, 08:00 ET D-Pharm Signs Deal With Jiangsu NHWA Pharmaceutical for Development and Commercialization of DP-VPA in China

D-Pharm Ltd. (TASE: DPRM) announced today that it has entered into a licensing and co-development agreement with Jiangsu NHWA Pharmaceutical Co.,...


Nov 03, 2010, 08:00 ET D-Pharm Ltd Appoints CRO for Clinical Development of DP-b99 in China

D-Pharm (TASE: DPRM) announced today the appointment of Hangzhou Tigermed Consulting Co., Ltd as the contract research organization to manage the...


Aug 10, 2010, 07:58 ET D-Pharm Receives Top-line Results From Cardiac Safety Study With DP-b99

D-Pharm Ltd (DPRM: TASE) announced today successful top-line results from a thorough electrocardiographic (ECG) study of DP-b99 in healthy...


Apr 15, 2010, 08:00 ET D-Pharm Receives Agreement Letter on Special Protocol Assessment for DP-b99 Study - a Pivotal Phase III Trial in Acute Ischemic Stroke Patients

D-Pharm Ltd (DPRM: TASE) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol...


Dec 31, 2009, 08:00 ET D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI

D-Pharm Ltd (TASE: DPRM) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first...


Aug 17, 2009, 08:00 ET D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)

D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage...


Jun 08, 2009, 08:00 ET D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients

D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic...


May 06, 2009, 08:01 ET D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients

D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for...


Apr 07, 2008, 01:00 ET D-Pharm Secures Funding From Israel's Chief Scientist's Office

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its...


Mar 04, 2008, 00:00 ET D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99

REHOVOT, Israel, March 4 /PRNewswire/ -- D-Pharm announced today that it has held its Pre-IND (Investigational New Drug) meeting with the FDA to...